Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Rapport Therapeutics (RAPP) Equity Average (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Equity Average data on record, last reported at $478.1 million in Q1 2026.

  • On a quarterly basis, Equity Average rose 61.72% to $478.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $478.1 million, a 61.72% increase, with the full-year FY2025 number at $395.0 million, up 182.38% from a year prior.
  • Equity Average reached $478.1 million in Q1 2026 per RAPP's latest filing, down from $498.1 million in the prior quarter.
  • Over the last five years, Equity Average for RAPP hit a ceiling of $498.1 million in Q4 2025 and a floor of -$32.6 million in Q1 2024.
  • A 4-year average of $242.2 million and a median of $295.6 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 3026.83% in 2024, then increased 17.44% in 2025.
  • Tracing RAPP's Equity Average over 4 years: stood at -$19.4 million in 2023, then surged by 1722.0% to $314.3 million in 2024, then soared by 58.51% to $498.1 million in 2025, then fell by 4.03% to $478.1 million in 2026.
  • Business Quant data shows Equity Average for RAPP at $478.1 million in Q1 2026, $498.1 million in Q4 2025, and $387.6 million in Q3 2025.